Mirum Pharmaceuticals Inc.
MIRM | NASDAQ
$92
+$0.17 (+0.19%)
At close: Sep 21, 2026, 4:00 PM ET
$92.50
+$0.50 (+0.54%)
Pre-market:
Sep 22, 2026, 5:37 AM ET
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer & Director |
| Douglas T. Sheehy | Chief Legal Officer & Secretary |
| Eric H. Bjerkholt | Chief Financial Officer |
| Erin Campany | Chief People Officer |
| Peter Radovich | Chief Operating Officer & President |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations |
| Jean-Luc Girardet | Chief Technical Officer |
| Joanne J. Quan | Chief Medical Officer |
| Lara Longpre | Chief Development Officer |
| Meredith Kiernan | Senior Director of Global Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
Mirum Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jul 17, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 433 |
| CEO | Christopher Peetz |
Contact Details
989 East Hillsdale Boulevard Foster City,
California 94404 United States
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| SIC Code | 2834 |
Recent News
- 5 days ago / seekingalpha.comMirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 5 days ago / seekingalpha.comMirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events
- 12 days ago / seekingalpha.comMirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- 14 days ago / businesswire.comMirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
- 18 days ago / zacks.comWhy Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
- 20 days ago / businesswire.comMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- 28 days ago / defenseworld.netBlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRM
- 2 months ago / zacks.comMirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
- 2 months ago / seekingalpha.comMirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
- 2 months ago / marketbeat.comMirum Pharmaceuticals Q2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove MIRM